1. Introduction {#s0005}
===============

Uterine neuroectodermal tumors (NETs) are uterine neoplasms with a poor prognosis ([@bb0060]; [@bb0065]; [@bb0120]; [@bb0140]). They are pathologically classified into 2 groups: 1) those resembling central nervous system (CNS) embryonal tumors (central-type NETs) ([@bb0065]; [@bb0100]; [@bb0140]), and 2) those resembling peripheral primitive neuroectodermal tumors/Ewing sarcomas (peripheral-type NETs) ([@bb0060]; [@bb0120]; [@bb0140]). Uterine NETs are also associated with endometrial adenocarcinomas, carcinosarcomas, and high-grade sarcomas ([@bb0140]). However, the pathogenesis of NETs remains unknown because of the rarity of this type of malignancy ([@bb0060]; [@bb0065]; [@bb0120]; [@bb0140]). Here, we present a patient with a rare uterine NET comprising frequent ganglion-like cells.

2. Case report {#s0010}
==============

A 62-year-old Japanese woman was receiving medications for cellulitis and deep vein thrombosis of her right and left lower extremities. During follow-up visits for these ailments, contrast-enhanced computed tomography (CT) revealed a solid uterine tumor exhibiting heterogeneous enhancement ([Fig. 1](#f0005){ref-type="fig"}A) with multiple swollen intra-pelvic and para-abdominal aortic lymph nodes. The uterine mass exhibited hypointensity and high intensity on T1-weighted ([Fig. 1](#f0005){ref-type="fig"}B) and T2-weighted ([Fig. 1](#f0005){ref-type="fig"}C) pelvic magnetic resonance imaging, respectively. As the patient also complained of vaginal bleeding, she was admitted to our hospital for further examinations. Blood tests revealed elevated levels of the following tumor markers: carcinoembryonic antigen, 14.8 ng/mL (normal, \<5 ng/mL); carbohydrate antigen (CA) 19-9, 1300 U/mL (normal, \<40 U/mL); CA125, 68 U/mL (normal, \<35 U/mL); and neuron-specific enolase (NSE), 77.4 ng/mL (normal, \<16.3 ng/mL). Endometrial biopsy was performed, and the specimen was diagnosed as a leiomyosarcoma. There were para-abdominal aortic lymph node metastases ([Fig. 1](#f0005){ref-type="fig"}D), resulting hydronephrosis of both kidneys ([Fig. 1](#f0005){ref-type="fig"}E). One month later, the patient underwent total abdominal hysterectomy (TAH), bilateral salpingo-oophorectomy (BSO), and partial omentectomy. However, her renal dysfunction did not improve and her general condition gradually worsened to a level that precluded postoperative chemotherapy or radiation therapy. She died of multiple organ failure 2 months after the discovery of the tumor.Fig. 1Radiological features of the uterine tumor and hydronephrosis. Contrast-enhanced computed tomography (CT) showed the large solid uterine tumor with heterogeneous enhancement (A). Magnetic resonance imaging showed the uterine tumor with slightly heterogeneous hypointensity on T1-weighted imaging (B) and hyperintensity on T2-weighted imaging (C). CT showed prominent para-aortic lymph node metastases (D), resulting bilateral hydronephrosis (drip infusion pyelography; E).Fig. 1

3. Pathologic findings {#s0015}
======================

The resected uterus comprised almost entirely of a milky-whitish tumor with necrosis, measuring 15 × 9 cm in size ([Fig. 2](#f0010){ref-type="fig"}A). The tumor was histopathologically classified as a highly malignant cellular neoplasm ([Fig. 2](#f0010){ref-type="fig"}B) and was mainly composed of small naked neoplastic cells ([Fig. 2](#f0010){ref-type="fig"}C). The following additional histological components were noted: atypical ganglion-like cells with a fibrillary background ([Fig. 2](#f0010){ref-type="fig"}D), endometrial adenocarcinoma with squamous differentiation ([Fig. 2](#f0010){ref-type="fig"}E), rhabdoid-like cells ([Fig. 2](#f0010){ref-type="fig"}F), atypical spindle cells resembling skeletal muscular cells, and an atypical cartilaginous component. The component comprising atypical ganglion-like cells with a fibrillary background occupied approximately 92% of the uterine tumor. The neoplasm directly infiltrated the parametrium and had metastasized to both ovaries as well as the major omentum.Fig. 2Macroscopic and histopathological features of the uterine neuroectodermal tumor. The uterus was almost totally occued by the neoplasm (A, sagittal section of the uterus). Histopathologically, the uterine tumor was a highly cellular neoplasm (B, hematoxylin and eosin \[H&E\]) mainly composed of small round neoplastic cells (C, H&E) and ganglion-like cells with fibrillary background (D, H&E). Moreover, components of adenocarcinoma with squamous metaplasia (E, H&E) and rhabdoid-like cells (F, H&E) were intermingled in the tumor.Fig. 2

Immunohistochemically, the small naked neoplastic cells showed varying degrees of immunoreactivity for vimentin, CD99, CD56, S100, synaptophysin ([Fig. 3](#f0015){ref-type="fig"}A), alpha-smooth muscle actin (α-SMA), neurofilament (NF), and chromogranin A (CGA). Both the atypical ganglion-like cells and fine fibrillary background were positive for synaptophysin ([Fig. 3](#f0015){ref-type="fig"}B), S100, CD56, CD99, and NF. The atypical ganglion-like cells were also positive for CGA. A few neuronal nuclei (NeuN)-positive atypical ganglion-like cells and glial acidic protein (GFAP)/oligodendrocyte lineage transcription factor 2 (Olig2)-positive fibrillary astrocytes were also detected ([Fig. 3](#f0015){ref-type="fig"}C). The endometrial adenocarcinoma with a squamous differentiation component was diffusely positive for cytokeratin (CK) AE1/AE3 ([Fig. 3](#f0015){ref-type="fig"}D) and epithelial membrane antigen (EMA), and was focally positive for vimentin. The squamous differentiation component showed p40 immunoreactivity. The rhabdoid-like cells revealed immunoreactivity for vimentin, synaptophysin, CGA, and NF, suggesting small ganglion cells, whereas it was negative for S-100, human melan black-45 (HMB-45), GFAP, Olig2, NeuN, epithelial markers (cytokeratin \[CAM5.2\], EMA, and pan-CK \[AE1/AE3\]), and muscular markers (desmin, myogenin, and α-SMA). Nuclear INI1 protein immunoreactivity was preserved in the tumor, including in the rhabdoid-like cells ([Fig. 3](#f0015){ref-type="fig"}E). α-SMA-positive atypical spindle cells were intermingled with the epithelial and neuronal components. The MIB-1 labeling index was \>50% in the small round neoplastic cells ([Fig. 3](#f0015){ref-type="fig"}F) and approximately 20% in the ganglion-like cells with fibrillary background. No neoplastic cells were positive for melanoma (HMB-45 and melan-A) or skeletal muscle (desmin and myogenin) markers. Based on these features, the pathological diagnosis was uterine NET with frequent ganglion-like cells.Fig. 3Immunohistochemical features of the uterine neuroectodermal tumor. Small round neoplastic cells (A) and ganglion-like cells with fibrillary background (B) showed immunoreactivity for synaptophysin. Furthermore, glial acidic protein (GFAP)-positive astrocytes were also intermingled (C, GFAP), suggesting a central-type neuroectodermal tumor. The adenocarcinoma component was immunopositive for cytokeratin AE1/AE3 (D, AE1/AE3). Nuclear INI1 protein expression was preserved in the tumor, including in the rhabdoid-like cells (E, INI1). The tumor showed a high MIB-1 labeling index at the area of small round neoplastic cells (F, Ki-67).Fig. 3

Widespread dissemination of the uterine NET was found on autopsy. The uterine neoplastic cells had metastasized or disseminated to the lungs, liver, appendix vermiformis, urinary bladder, ureters, Douglas\' pouch, peritoneum, mesenterium, and lymph nodes (para-aortic, peri-tracheal, and peri-pancreatic). The metastatic cells were mainly comprised of NET with ganglion-like cells and a fibrillary background; however, no metastases of the carcinomatous or sarcomatous components were noted. Both kidneys showed mild hydronephrosis that was secondary to tumor spreading. No remarkable changes were noted in the heart, alimentary tract, pancreas, gallbladder, thyroid gland, or adrenal glands.

4. Discussion {#s0020}
=============

Uterine NET is rare; only 69 patients with this tumor type have been reported in the English-language literature to date ([Table 1](#t0005){ref-type="table"}). Clinically, uterine NET usually occurs in postmenopausal women and presents with vaginal bleeding ([@bb0065]; [@bb0140]). Indeed, 78.7% of the patients with uterine NETs listed in [Table 1](#t0005){ref-type="table"} experienced vaginal bleeding, and 72.9% of them were over 40 years old. Approximately 50% of these uterine neoplasms are found to have metastasized to the extra-uterine tissues/organs at diagnosis ([@bb0140]). The major metastatic sites of uterine NETs are the lymph nodes via the lymphatic system ([@bb0045]; [@bb0125]; [@bb0160]; [@bb0130]; [@bb0060]) and lungs/liver via the vasculature ([@bb0015]; [@bb0080]; [@bb0085]; [@bb0160]; [@bb0175]; [@bb0205]), as was also observed in our patient. Although the standard treatment for uterine NETs normally involves surgery (TAH + BSO) with or without chemotherapy and/or radiotherapy ([@bb0060]), we recommend that lymph node dissection also be performed when possible. However, the necessity of omentectomy in patients with uterine NETs remains unconfirmed because it has been performed in too few patients who underwent TAH + BSO ([Table 1](#t0005){ref-type="table"}).Table 1Clinicopathological feature of 69 uterine neuroectodermal tumor cases.Table 1Case noAge (y.o)SymptomFIGO stageSurgeryPostoperative therapyPrognosisPathological findingsReferenceCTRTAlive/diedFollow-up (month(s))Tumor size (cm)ComponentMetastasisMajor componentMinor componentGanglion cells158Vaginal bleedingIIIc+ (unknown detail)−−DOD2NDNET−−ND[@bb0065]Palpable mass231Back paineIV−+ (unknown regimen)+DOD20NDNET−−ND[@bb0065]372Vaginal bleedingIaNDNDNDDOD11NDNET−−ND[@bb0065]448NDIIIcNDNDNDNDNDNDEM carcinomaNET−ND[@bb0065]581Vaginal bleedingNDNDNDNDNDNDNDNET--−ND[@bb0065]666Pelvic massIIIc+Letrozole−NED41NDNETHigh grade sarcoma−ND[@bb0065](unknown detail)753Vaginal bleedingNDNDNDNDDOD22NDNET−−ND[@bb0065]851Vaginal bleedingNDNDNDNDDOD12NDNET−−ND[@bb0065]931Vaginal bleedingNDNDNDNDDOD26NDNETEM hyperplasia with atypia−ND[@bb0065]1064Endocervical polypIIbTAH, BSO++NED36NDNET−−ND[@bb0065](unknown regimen)1164Vaginal bleedingNDNDNDNDNDNDNDAdenosarcomaNET−ND[@bb0065]Pain1269Vaginal bleedingIVNDNDNDNDNDNDNETRhabdomyosarcoma−ND[@bb0065]1362Uterine fibroidsIIIcNDNDNDDOD22NDNET−−ND[@bb0065]1455Vaginal spottingIbTAH, BSO+−NED38NDNET−−ND[@bb0065](unknown regimen)1552NDIVNDNDNDNED6NDNET−−ND[@bb0065]1658Vaginal pressureIV−+−NED6NDCarcinosarcomaNET−ND[@bb0065](unknown regimen)1757NDIIIc−+−NED35NDCarcinosarcomaNET+ND[@bb0065](unknown regimen)1812Vaginal bleedingIVTAH, LSOCyclophosphamide−DOD25NDNET−+Lung[@bb0085]DoxorubicinAdriamycinDactinomycinVincristine1957Vaginal bleedingIIIcTAH, BSO, PALNDCisplatin+DOD24NDNET−+Lung[@bb0085]VinblastineRetroperitoneumBleomycin2017Vaginal bleedingIIIcTAH, PLND, left uretectomy,Vincristine−NED10NDNET−+−[@bb0150]Pelvic massbilateal ovarian wedge biopsyCisplatinDaunorubicinDactinomycinCyclophosphamideEtoposide2167Vaginal bleedingIIIcSTAH, BSOCisplatin+DOD6NDNET−ND−[@bb0045]Enlarged uterusDoxorubicinCarboplatin5-FU2268Vaginal bleedingIVbTAH, BSO, PLND−+DOD127.5NET−+LNs (supraclavicular)[@bb0045]2369Vaginal bleedingITAH, BSO, PLND−+NED722NETEM stromal sarcomaND−[@bb0045]2468Vaginal bleedingITAH, BSO−−NED602NETEM carcinomaND--[@bb0045]2572Vaginal bleedingIbTAH, BSO−−DOD86.5 × 3.5 × 3.0NET--−ND[@bb0110]2654Vaginal bleedingIIIaTAH, BSO, PLNDCyclophosphamide−AWD38.5 × 8.0 × 6.5NETCarcinosarcoma−−[@bb0075]Cisplatinadriamycin5-FU2778Vaginal bleedingIbTAH, BSO, PLND−−NED96NETCartilaginous component−−[@bb0070]2862Vaginal bleedingIbTAH, BSOVincristine+DOD184 × 2NET−−Terminal ileum[@bb0180]CyclophosphamideCecumCisplatintenisopid2936Enlarged uterusIbRH, BSO, PLND−+NDND11NET−−−[@bb0190]3047NDIIbTAH, BSO, LND++DOD187.8NETEndometrioid carcinomaPelvis[@bb0175](unknown regimen)3167NDIIIcTAH, BSO, LND+−DOD34.5NETEM carcinomaPeritoneum[@bb0175](unknown regimen)3271NDIIIcTAH, BSO, LND+−DOD46NETEM carcinomaLung[@bb0175](unknown regimen)Peritoneum3316Vaginal bleedingIcTAH, BSO, omentectomyVincristine+NED48NDNET−−−[@bb0090]CyclophosphamideDoxorubicin3448Vaginal bleedingIIIcTAH, BSO−−NED6NDNETEM carcinoma−−[@bb0115]Pelvic mass3568Vaginal bleedingITAH, BSO−−NED10NDNET−−ND[@bb0200]3666Vaginal bleedingIaTAH, BSO, omentectomyND−NED244 × 3.5 × 2NET−−--[@bb0125]PLND, PALND3765Vaginal bleedingIIIcTAH, BSO, PLND, PALND,Cisplatin+AWD127NET−−Vagina[@bb0125]omentectomy, upper vaginectomyAdriamycinObturator lymph nodesEtoposide3815Abdominal peinITAH, PLNDCarboplatin−NED126 × 7NET−−−[@bb0135]Pelvic massEtoposide3943Vaginal bleedingIIIcTAH, BSO, PLNDCytoxan−NED213.3NET−−Left adnexa[@bb0195]Uterine enlargementAdriamycinVincristineEtoposide4058Vaginal bleedingIVTAH, BSO, right PLND,Carboplatin−DOS1112NETEM carcinoma−Lung[@bb0015]Abdominal painsegmental enterectomy,Paclitaxeltotal coloectomy4126Vaginal bleedingIVTAH, BSO, PLND, omentectomyCisplatin−NED485.8 × 4.2NET−−−[@bb0120]EtoposideAvastin4250Abdominopelvic painNDTAH, BSO, omentectomyCarboplatin−NED1615NET−−−[@bb0050]Etoposide4363Vaginal bleedingIIIcTAH, BSO, LNDIfosfamide−DOD75.0 × 4.5 × 3.0NETRhabdomyosarcoma−Pelvis[@bb0055]CisplatinMesenteriumPeritoneum4480Abdominal painIbTAH, BSO, LND−+AWD65.0 × 4.0 × 3.0NETEM carcinoma−Intraabdominal metastasis[@bb0055]4579Vaginal bleedingIbTAH, BSO, LND−−NED294.5 × 3.0 × 3.0NETEM carcinoma−−[@bb0055]4678Vaginal bleedingIIIaTAH, BSO, LND−−NED87.5 × 7.0 × 5.5NET−−−[@bb0055]4732Abdominal painIIIaTAH, BSO, PLND, PALND,Cisplatin+AWD383NET−−−[@bb0035]omentectomy, appendectomyIfosfamideAdriamycinVincristine4866Vaginal bleedingIVbTAH, BSOCisplatin+DOD246 × 4CarcinosarcomaNETLung[@bb0080]Pelvic painCyclophosphamideLNs (left supraclavicula, right axillary)DoxorubicinDexamethasone4932Vaginal bleedingIVTAH, BSO, PLNDHoloxan−AWD249 × 6.5NET−−Peritoneal seeding[@bb0010]Abdominal painMensCisplatinPaclitaxelCarboplatin5029Abdominal swelling and painIVbSTAH, BSO, PLND, omentectomy,Docetaxel+AWD183.0 × 2.5 × 2.0NET−−Liver[@bb0205]appendectomy,Carboplatinmetastatic nodule resectionVincristineAdriamycinCyclophosphamideIfosfamideEtoposide5163ConstipationNDTAH, BSOCyclophosphamide−NED2413.0 × 10.0NET−−−[@bb0165]VincristineAdriamycin5225Vaginal bleedingNDTAH, BSOVincristine+NED187.6 × 4.0 × 5.9RhabdomyosarcomaNET−Vagina[@bb0030]AdriamycinCyclophosphamideIfosfamideEtoposide5312Vaginal bleedingND−Etoposide−NED3612RhabdomyosarcomaNET−[@bb0185]CisplatinBleomycin5456Vaginal bleedingIbTAH, BSO, PLNDIfosfamide−NED414.0 × 3.5 × 2.0NET−−−[@bb0145]EtoposideCisplatin5559vaginal bleedingIIIcTAH, BSO, PLND, PALND,Carboplatin+AWD121.1NET−−Lymph nodes (mediastinal, paraaortic)[@bb0160]omentectomyPaclitxelVaginal cuffCisplatinpelvic wallLungliver5630Vaginal bleedingIVb−Doxorubicin+DOD1618 × 20 × 21NET−−Lymph nodes (paraaortic, pelvic)[@bb0130]IfosfamideOmentumVincristineThoracolumbar spineCarboplatinRight humerusEtopisideLeft lower ribDocetaxelLeft femurIrinotecanCelecoxib5722Vaginal bleedingITAH, BSO, PLND, PALND,Cisplatin−NED107.6 × 6.1NET−−−[@bb0005]Adnexal massomentectomyDoxorubicin−5824FeverIITAH, BSO, omentectomyVincristine−AWD19 × 10NET−−Residual tumor[@bb0105]Lower abdominal painAdriamycinCyclophosphamideIfosfamideEtoposide5926Pelvic massIIIModified TAH, PLND,Vincristine+NED167.0 × 5.0NET−−−[@bb0025](found at cesarean section)bilateral ovarian transpositionDoxorubicinCytoxanMensaifosfamideEtoposide6050Vaginal bleedingIIIcTAH, BSO, PLND,++NED610 × 8NETAdenosarcoma−Vaginal vault[@bb0020]omentectomy(unknown regimen)6151Vaginal bleedingIIITAH, BSO+−NDNDNDNETEM carcinoma−ND[@bb0040](unknown regimen)6250Vaginal bleedingIIITAH, BSO−−NDNDNDNETEM carcinoma−ND[@bb0040]6331Vaginal bleedingIIITAH, BSO−−NDNDNDNETCarcinosarcoma−ND[@bb0040]6426Vaginal bleedingITAH, BSO−−NDNDNDNET−−ND[@bb0040]6564NDIIITAH, BSO+−NDNDNDNET−−ND[@bb0040](unknown regimen)66NDNDNDTAH, BSONDNDNDNDNDNET−−ND[@bb0040]6760Vaginal bleedingIVTAH, BSO, PALNDCarboplatin−NDND10 × 13NET−−Pelvis[@bb0060]Abdominal peinEtoposideLNs (para-aortic, retropetitoneal)6831Vaginal bleedingIIIc+Cisplatin+NED24NDNET−−/Tsai et al. (2012)Abdominal pain(unknown detail)Etoposide6962Vaginal bleedingIVbTAH, BSO, omentectomy−−DOD215 × 9NETCarcinosarcoma+Peritoneumpresent caseLiverAppendix vermiformis[^1]

As for the prognosis of patients with uterine NETs, [@bb0065] reported a mortality rate of 47% in their largest uterine NET series; furthermore, the 2-year survival rate of postmenopausal patients with uterine NET was reported to be approximately 30% ([@bb0060]; [@bb0140]). Consistent with previous reports, our patient was also a postmenopausal woman with minimal vaginal bleeding, and had a uterine tumor with lymphadenopathy at the time of diagnosis. She died 2 months after the uterine mass was diagnosed despite undergoing TAH, BSO, and omentectomy; however, lymph node dissection was not possible. As such, our patients\' uterine NET was consistent with previously reported tumors that had poor prognoses. Of the 69 patients with uterine NETs previously reported in the English-language literature ([Table 1](#t0005){ref-type="table"}), 36% died of their uterine tumors after a mean post-surgical duration of 14.1 months (range, 2--26 months), 50% were free of disease after a maximum follow-up period of 72 months, and 14% were alive with disease after a maximum follow-up period of 38 months. Furthermore, the mean follow-up duration from diagnosis to death in the non-surviving patients was 14.5 ± 8.4 months. Taken together, uterine NETs may not necessarily have as poor a prognosis as previously thought ([@bb0060]; [@bb0065]; [@bb0120]; [@bb0140]).

The histopathology of uterine NET is characterized by a monotonous population of small- to medium-sized round neoplastic cells growing in sheets, nests, and/or cords, with or without fibrillary backgrounds and rosette formations ([@bb0065]; [@bb0140]). Some central-type NETs have been reported to show pathological features similar to those of medulloblastoma, medulloepithelioma, glioblastoma, and/or ependymoma ([@bb0040]). Uterine NETs may also include other histologic elements, such as endometrial adenocarcinoma, carcinosarcoma, and/or high-grade sarcoma ([@bb0065]; [@bb0140]). Our patient\'s uterine NET had heterologous carcinosarcoma as a minor component, which has also been described in previous reports ([@bb0065]; [@bb0140]). However, frequent ganglion-like cells with a fibrillary background were detected as a major component in our patient, whose NET resembled a ganglioneuroblastoma ([@bb0100]). To the best of our knowledge, this uterine NET subtype is extremely rare, although a patient with a uterine NET comprising foci resembling ganglioneuroma was reported by [@bb0085].

Immunohistochemical analyses of our patient\'s tumor showed that the NET component expressed CD99, synaptophysin, NSE, and NF. Although rare, GFAP immunoreactivity is characteristic of CNS-type NETs ([@bb0140]). In addition to neuronal markers such as synaptophysin and NF, our patient\'s tumor also expressed the glial markers GFAP and Olig2. Moreover, an α-SMA immunoreactive spindle cell component and both a vimentin and epithelial marker immunoreactive component were detected, suggesting leiomyosarcoma and endometrial adenocarcinoma, respectively, intermingled as minor components within the neuroectodermal component. *EWSR1* rearrangement has been recently reported as a characteristic genetic finding of peripheral-type uterine NETs ([@bb0120]); however, we were unable to perform genetic analysis to test for *EWSR1* rearrangement.

Surgery (TAH + BSO) with or without chemotherapy and/or radiotherapy is the standard treatment for uterine NETs ([@bb0060]). As described in [Table 1](#t0005){ref-type="table"}, approximately 92% of patients with uterine NETs underwent surgery, while 72% received chemotherapy and only 36% received radiotherapy. Therapeutic treatment regimens for gynecologic NETs might be selected according to their subtypes, such as NETs resembling medulloblastoma and Ewing sarcoma/peripheral primitive NETs ([@bb0040]). Furthermore, [@bb0120] recently reported a patient with uterine NET treated with surgery and adjuvant chemotherapy using cisplatin, etoposide, and bevacizumab; their patient experienced no recurrence for 48 months. Although our patient was treated with TAH + BSO, she died of multiple organ failure 1 month after surgery owing to the metastasis of multiple tumors that comprised mainly of NET resembling ganglioneuroblastoma (according to autopsy results). In retrospect, treating the ganglioneuroblastoma with total tumor resection followed by chemoradiotherapy with temozolomide should have been considered for our patient, as it was previously reported that 2 patients with cerebral ganglioneuroblastoma treated with this regimen were free of tumor recurrence or progression after 12 and 14 months of follow-up, respectively ([@bb0155]). Interestingly, as shown in [Table 1](#t0005){ref-type="table"}, 42% of the patients with uterine NETs who underwent radiotherapy died of their disease, whereas 32% were free of disease. Although surgery with or without chemotherapy and/or radiotherapy is the standard treatment for uterine NETs ([@bb0060]), postoperative radiotherapy for such patients might need to be reconsidered. Nevertheless, the accumulation of additional patient data and detailed clinical and pathological analyses are required to devise better treatment modalities for uterine tumors.

Although the pathogenesis of primary uterine NETs remains poorly understood, several possibilities have been suggested, including 1) that they originate from the implantation of aborted fetal tissue in the uterus ([@bb0040]; [@bb0075]; [@bb0150]; [@bb0170]; [@bb0210]), 2) that they originate from abnormal migrated neural crest cells in the uterus ([@bb0040]; [@bb0075]; [@bb0150]), and 3) that they are of Müllerian origin ([@bb0040]; [@bb0045]; [@bb0075]; [@bb0080]; [@bb0210]). [@bb0095] reported that malignant mixed Müllerian tumors showed GFAP immunoreactivity; our patient had heterologous carcinosarcoma intermingled within the uterine NET as the minor component. Based on our clinicopathological findings, our patient\'s tumor appeared to have been of Müllerian origin.

In conclusion, uterine NETs with frequent ganglion-like cells such as the tumor diagnosed in our patient are extremely rare; their pathogenesis is poorly understood and afflicted patients have poor prognoses. Therefore, the accumulation of clinicopathological data from additional patients is needed to establish more effective treatment modalities for patients with these types of tumors.

Author contributions {#s0025}
====================

Taku Homma: Pathological examination, manuscript preparation.

Takehiro Nakao: Patient care, data collection.

Toshiya Maebayashi: Radiology imaging examination.

Toshiyuki Ishige: Pathological examination.

Hiroyuki Hao: Supervisor, manuscript preparation.

Funding disclosure {#s0030}
==================

This study did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of interest {#s0035}
====================

The authors declare no conflicts of interest.

The authors thank Mrs. Yukari Hirotani of the Department of Pathology, Nihon UniversitySchool of Medicine for her excellent technical assistance.

[^1]: y.o., years old; FIGO, International Federation of Gynecology and Obstetrics; TAH, total abdominal hysterectomy; BSO, bilateral salpingo-oopholectomy; PLND, pelvic lymph node dissection; PALND, paraaortic lymph node dissection; CT, chemotherapy; RT, radiation therapy; DOD, die of disease; NED, no evidence of disease; AWD, alive with disease; ND, no data; NET, neuroectodermal tumor; EM, emdometrial
